Literature DB >> 28027175

Surgical Management of Duplication of the Pituitary Gland-Plus Syndrome With Epignathus, Cleft Palate, Duplication of Mandible, and Lobulated Tongue.

Tadahide Noguchi1, Tomoko Sugiyama, Ken-Ichi Sasaguri, Shigeru Ono, Kosaku Maeda, Hiroshi Nishino, Yoshinori Jinbu, Yoshiyuki Mori.   

Abstract

A 1-day-old male infant was referred to our department for evaluation of multiple malformations in his oral cavity. He was diagnosed duplication of the pituitary gland-plus syndrome with epignathus, cleft palate, duplication of the mandible, and a lobulated tongue. A thumb-sized mass lesion was visible on the hard palate. The duplicated mandible and lower lip was fused at the midline. The alveolar ridge was protruding through a wide-cleft soft palate involving the uvula. Further examination showed a lobulated tongue, which was seen behind the duplicated part of the mandible. Five days after birth, tracheotomy and epignathus resection were performed. At 7 months of age, the excess tissue of the duplicated mandible was resected at the area of adhesion on the lingual side, and the duplicated tongue and lip were reconstructed. A palatoplasty was performed at 20 months of age. Thereafter, the patient's progress was uneventful, with no abnormality in swallowing. No recurrence of epignathus has been observed during 2 years of follow-up.

Entities:  

Mesh:

Year:  2017        PMID: 28027175     DOI: 10.1097/SCS.0000000000003324

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Duplication of the oral cavity and mandible: a rare congenital craniofacial anomaly.

Authors:  Alexandra O Hamberis; David Macias; Clarice Clemmens; Krishna G Patel
Journal:  BMJ Case Rep       Date:  2020-05-19

2.  Alimentary tract duplications in children - a 15 years' experience.

Authors:  Radu Iulian Spătaru; Mircea Ovidiu Denis Lupuşoru; Dragoş Şerban; Monica Ivanov; Dan Alexandru Iozsa
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.